The lancet. Psychiatry
October 1, 2023
Gustavo C Medeiros, Malcolm Matheson, Isabella Demo et al.
38 citations
A systematic review of 69 neuroimaging studies (1751 participants) found no well-replicated biomarker for ketamine's antidepressant response, but identified several promising candidates. Response to ketamine was associated with post-treatment increases in gamma power in frontoparietal regions, increased functional connectivity within the prefrontal cortex, and increased functional activation of the striatum. The review highlights substantial methodological heterogeneity across studies and calls for further investigation of these biomarkers.
Mindfulness
April 1, 2023
Carly Hunt, Janelle E. Letzen, Samuel R Krimmel et al.
9 citations
A secondary analysis of a clinical trial compared a 12-week enhanced mindfulness-based stress reduction course (MBSR+) to stress management for headache in 98 migraine patients. Greater pre-treatment functional connectivity between the ventromedial prefrontal cortex and right nucleus accumbens predicted more meditation practice during MBSR+ and larger reductions in headache frequency. Participants who meditated more showed increased mindfulness and reduced helplessness related to pain, but not improvements in headache frequency, severity, or impact. Increased mindfulness mediated reductions in headache impact but not frequency. The findings suggest mesocorticolimbic system function relates to motivated behavior, and motivation-enhancing interventions might boost meditation engagement.
EClinicalMedicine
September 24, 2025
Megan Hosein, Matthew J Reid, Sarah A. Walser et al.
5 citations
Psilocybin and other psychedelics show promise as a new class of psychiatric treatments, but their rapid development risks outpacing the guidelines and infrastructure needed for safe clinical integration. A consensus statement from the US National Network of Depression Centers (NNDC) Task Group on Psychedelics and Related Compounds, comprising psychiatrists, psychologists, neuroscientists, psychedelic researchers, and healthcare consultants, recognizes psilocybin's therapeutic potential while emphasizing the need for further research. Key gaps include understanding therapeutic dosage, efficacy across diverse populations, and long-term safety. The authors call for diversified funding, collaborative research, standardized provider training, and careful ethical consideration. They advocate for a balanced approach prioritizing rigorous science and equitable access, noting the single-country focus limits international generalizability.
Current Psychiatry Reports
November 1, 2024
Matthew J Reid, Hannes Kettner, Tessa F. Blanken et al.
4 citations
Psilocybin is an emerging treatment for depression, but its effects on sleep are not well understood. Clinical trials show large improvements in depressive symptoms, but sleep quality or insomnia symptoms have not been directly studied. Preliminary data indicate that both depressive symptoms and sleep disturbances decreased significantly after psilocybin use, though sleep improvements were smaller than those for depression. More severe sleep disturbances at baseline were linked to a lower probability of depression remission, suggesting a potential interaction between sleep and psilocybin's efficacy. Addressing sleep disturbances could enhance therapeutic outcomes and lead to more personalized treatment strategies.
Curr Psychiatry Rep
June 5, 2026
Matthew J Reid, Hannes Kettner, Tessa F. Blanken et al.
correction
A correction notice was issued for a previously published article on psilocybin administration and sleep improvements. The correction addresses errors in the original text but does not provide new findings or data.
Journal of psychopharmacology (Oxford, England)
February 5, 2026
Benjamin R. Lewis, Matthew J Reid, Andrew M Novick et al.
Clinical trials of classical psychedelics like psilocybin for mental health conditions face unique challenges that may persist if these treatments enter clinical practice. Four categories of challenges with trial participants are identified: treatment nonresponse, expectancy effects and functional unblinding, post-session psychological difficulties, and contagion effects. Management strategies for study teams to mitigate these risks are described. The National Network of Depression Centers and similar organizations can guide best practices to responsibly advance this promising field.